Phase 2 Study to Test Safety and Effectiveness of One Oral Dose of LY4515100 for Moderate-to-Severe Pain After Surgical Removal of Impacted Wisdom Teeth

What this Trial Is About

Researchers are evaluating LY4515100 to assess its safety and how well it works compared with a placebo for treating moderate-to-severe acute pain after surgical removal of impacted third molars. This phase 2, randomized, double-blind study focuses on pain relief following this common oral surgery. The trial involves participants aged 18 to 40 years who require extraction of multiple third molars with certain impactions confirmed by X-ray. Participants will receive a single oral dose of either LY4515100 or a placebo. After surgery, each participant will stay in a Clinical Research Unit for monitoring. The study includes measures of pain intensity, pain relief, time to use of rescue medication, and the drugs concentration in the body, all tracked up to one day after dosing. During the approximately six-week study, participants will undergo assessments of their pain levels and relief using numerical and categorical scales. Researchers will also monitor safety through clinical evaluations and laboratory tests. The trial collects data on how quickly pain decreases and participants overall impression of pain relief, aiming to understand the drugs effects and safety profile in this setting.

A Study of LY4515100 in Participants With Pain Following Third Molar Removal